TC BIOPHARM HLDGS (TCBPY) Financials
Newest figures come from the 10-K for FY2024, filed May 9, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TCBPY SEC filings page.
This page shows TC BIOPHARM HLDGS (TCBPY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
TC BIOPHARM HLDGS does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
TC BIOPHARM HLDGS reported a net loss of $15.3M while operations used $15.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TC BIOPHARM HLDGS reported -$15.3M in net income in fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
TC BIOPHARM HLDGS held $1.5M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
TC BIOPHARM HLDGS's ROE was -402.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
None of these metrics is reported for fiscal year 2024.
TCBPY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K |
|---|---|
| Net Income | -$15.3M |
| Diluted Shares (Avg) | 377M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted).
TCBPY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K |
|---|---|
| Cash & Equivalents | $1.5M |
| Short-Term Investments | $0 |
| Long-Term Investments | $0 |
| Total Equity | $3.8M |
Not reported in any period shown, so not listed: Total Assets, Current Assets, Inventory, Accounts Receivable, Goodwill, Total Liabilities, Current Liabilities, Non-Current Liabilities, Long-Term Debt, Retained Earnings.
TCBPY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K |
|---|---|
| Operating Cash Flow | -$15.8M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
TCBPY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K |
|---|---|
| Return on Equity | -402.6% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Assets, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TC BIOPHARM HLDGS TCBPY | FY2024 | N/A | -$15.3M | N/A | $12K | — |
| VIRACTA THERAPEUTICS INC VIRX | FY2023 | N/A | -$51.1M | N/A | $6.0M | — |
Where TC BIOPHARM HLDGS Ranks
Frequently Asked Questions
Is TC BIOPHARM HLDGS profitable?
No, TC BIOPHARM HLDGS (TCBPY) reported a net income of -$15.3M in fiscal year 2024.
What is TC BIOPHARM HLDGS's return on equity (ROE)?
TC BIOPHARM HLDGS (TCBPY) has a return on equity of -402.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is TC BIOPHARM HLDGS's operating cash flow?
TC BIOPHARM HLDGS (TCBPY) recorded an outflow of $15.8M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
How does TC BIOPHARM HLDGS's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, TC BIOPHARM HLDGS (TCBPY) held $1.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Are TC BIOPHARM HLDGS's earnings high quality?
TC BIOPHARM HLDGS (TCBPY) reported a net loss of $15.3M while operations used $15.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.